Biotech Series C Investors & VC Firms
600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.
Bain Capital Venture
BostonPre-Seed–Late Stage
43 people
Legend Capital
BeijingPre-Seed–Growth$2.9M – $156M
25 people
EQT Life Sciences
LuxembourgSeed–Late Stage$11M – $66M
39 people
Blue Venture Funds
ChicagoSeed–Late Stage$1M – $20M
25 people
B4 Capital
Pre-Seed–Late Stage$10M – $50M
VantagePoint Capital Partners
Silicon ValleySeed–Late Stage$2M – $100M
21 people
Casdin Capital
New YorkSeed–Series C
39 people
M Ventures
Los AngelesSeed–Growth$10.8M
9 people
Cross Creek Advisors
Salt Lake CitySeries B–Late Stage
19 people
Kyoto University Innovation Capital
KyotoPre-Seed–Growth
20 people
Primo Ventures
MilanPre-Seed–Growth$1.1M
18 people
Innovation Industries
AmsterdamSeed–Late Stage$2.2M – $54M
25 people
Kreos Capital
LondonSeries A–Late Stage
43 people
Ysios Capital
BarcelonaSeries A–Late Stage$5.4M – $21.6M
26 people
Artis Ventures
San FranciscoSeed–Late Stage$50K – $25M
7 people
Abingworth
LondonPre-Seed–Late Stage$15M – $30M
39 people
Ahren Innovation Capital
Cambridge, CambridgeshirePre-Seed–Late Stage
30 people
Agent Capital
WalthamPre-Seed–Late Stage
22 people
Fortune Venture Capital
ShenzhenSeed–Late Stage$425K – $73M
11 people
UntroD Capital
TokyoPre-Seed–Growth$772K – $241M
5 people
Medicxi
LondonPre-Seed–Late Stage
34 people
S32
Palo AltoSeries A–Late Stage
25 people
HealthCap
StockholmSeed–Growth
30 people
GroveStreet
NewtonSeries A–Late Stage
39 people
Related lists
Series C Investors & VC Firms (2751)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Biotech Series A Investors & VC Firms (1596)Biotech Investors & VC Firms in United States (1039)Series C Investors & VC Firms in United States (946)Biotech Series B Investors & VC Firms (900)Series C Investors & VC Firms in Global (896)Biotech Pre-Seed Investors & VC Firms (896)Healthtech Series C Investors & VC Firms (771)
Data sourced from public filings and firms' own websites — see our methodology.












































































